Real‐time quantitative PCR determination of urokinase‐type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients

Pierga, Jean‐Yves; Bonneton, C.; Magdelénat, H.; Vincent‐Salomon, Anne; Nos, Claude; Boudou, E; Pouillart, P; Thiery, Jean Paul; Crémoux, Patricia de

doi:10.1002/ijc.20698

Cited by 46 publications

(32 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have assessed DTC detection by using molecular biology techniques such as real-time quantitative PCR determination with several markers: CK19, MUC1,15 urokinase-type plasminogen activator receptor (uPAR), EpCAM16 and mammaglobin 17. This detection should be more sensitive (1 tumour cell in 107 mononuclear cells) and more effective.…”

Section: Methodologies For Detection Of Bone Marrow Micrometastasesmentioning

confidence: 99%

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

2007

View full text Add to dashboard Cite

Immunocytochemical detection of disseminated tumour cells in the bone marrow of patients with primary breast cancer at surgery has been shown to be an independent prognostic factor in single institutional studies and in a large pooled analysis. However, bone marrow sampling and assessment of disseminated tumour cells is not a routine procedure in the clinical management of patients with breast cancer, but will certainly play a role in the near future for risk stratification and monitoring of therapeutic efficacy. Accurate identification of disseminated tumour cells in bone marrow must be based on standardised methodologies and procedures. This review describes these methodologies and the standardised morphological criteria used for disseminated tumour cell detection. The prognostic value of circulating tumour cells detection in peripheral blood is demonstrated in patients with metastatic disease but remains to be substantiated at early stage. The significance of disseminated tumour cells in bone marrow and in the blood for the prediction of response to therapy is briefly summarised. Finally, this review addresses the main biological questions raised by disseminated tumour cells, in particular understanding tumour dormancy and identifying metastatic stem cells.

show abstract

Section: Methodologies For Detection Of Bone Marrow Micrometastasesmentioning

confidence: 99%

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

2007

View full text Add to dashboard Cite

show abstract

“…Expression changes in CTCs of assorted epithelial proteins (such as cytoskeleton-associated CKs, signaling kinases, growth factor receptors or surface adhesion molecules) may provide future science group organ-specific markers of increased metastatic potential [9, [121][122][123][124][125][126][127]. For example, altered protein expression in CTCs of ERBB2, CK18, CK19, CK20, MUC1 and CEA may be used as specific biomarkers for breast cancer aggressiveness [23,128] (reviewed in [6]).…”

Section: Characterization Of Protein Expression and Signaling In Ctcsmentioning

confidence: 99%

Organ-Specific Markers in Circulating Tumor Cell Screening: An Early Indicator of Metastasis-Capable Malignancy

Paterlini‐Bréchot

2011

Future Oncol.

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) represent an important biological link in the spread of primary solid tumors to the metastatic disease responsible for most cancer mortality. Their detection in the peripheral blood of patients with many different carcinomas has shown that tumor-cell dissemination can proceed at an early stage of tumor development and their presence is associated with poor clinical outcomes, particularly in metastatic disease. In this article we describe how the increasingly sensitive isolation and detailed molecular characterization of CTCs has greatly improved our understanding of metastatic proliferation. We focus on how CTC detection and knowledge of the molecular architecture of these cells can serve as biomarkers to signal metastasis-capable disseminating cells and predict therapy-specific response. This has marked clinical utility for improved selection of systemic therapies to the individual needs of a cancer patient, real-time monitoring of metastatic disease treatments and the development of new targeted therapies.

show abstract

“…67,68 DTC are heterogeneous with regard to the expression of growth factor receptors, adhesion molecules, proteases and their inducer and receptors, major histocompatibility complex antigens, signaling kinases, melanoma associated antigens (MAGE) or telomerase 1992 activity. 1,2,63,[69][70][71][72][73][74][75][76][77][78][79] Of particular importance is the epidermal growth factor receptor HER2, the expression of which in primary tumors is essential for Trastuzumab treatment decisions of breast cancer patients. 80,81 HER2 overexpression on DTC in BM was predictive for a poor clinical outcome of stage I-III breast cancer patients.…”

Section: Molecular Detection Of Dtcmentioning

confidence: 99%

Review: Biological relevance of disseminated tumor cells in cancer patients

Riethdorf

Wikman

Pantel

2008

Intl Journal of Cancer

290

236

View full text Add to dashboard Cite

The prognosis of cancer patients is largely determined by the occurrence of distant metastases. In patients with primary tumors, this relapse is mainly due to clinically occult micrometastasis present in secondary organs at primary diagnosis but not detectable even with high resolution imaging procedures. Sensitive and specific immunocytochemical and molecular assays enable the detection and characterization of disseminated tumor cells (DTC) at the single cell level in bone marrow (BM) as the common homing site of DTC and circulating tumor cells (CTC) in peripheral blood. Because of the high variability of results in DTC and CTC detection, there is an urgent need for standardized methods. In this review, we will focus on BM and present currently available methods for the detection and characterization of DTC. Furthermore, we will discuss data on the biology of DTC and the clinical relevance of DTC detection. While the prognostic impact of DTC in BM has clearly been shown for primary breast cancer patients, less is known about the clinical relevance of DTC in patients with other carcinomas. Current findings suggest that DTC are capable to survive chemotherapy and persist in a dormant nonproliferating state over years. To what extent these DTC have stem cell properties is subject of ongoing investigations. Further characterization is required to understand the biology of DTC and to identify new targets for improved risk prevention and tailoring of therapy. Our review will focus on breast, colon, lung, and prostate cancer as the main tumor entities in Europe and the United States.

show abstract

Real‐time quantitative PCR determination of urokinase‐type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients

Cited by 46 publications

References 41 publications

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues

Organ-Specific Markers in Circulating Tumor Cell Screening: An Early Indicator of Metastasis-Capable Malignancy

Review: Biological relevance of disseminated tumor cells in cancer patients

Contact Info

Product

Resources

About